Cargando…

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England

Adults receiving heterologous COVID-19 immunisation with mRNA (Comirnaty) or adenoviral-vector (Vaxzevria) vaccines had higher reactogenicity rates and sought medical attention more often after two doses than homologous schedules. Reactogenicity was higher among ≤ 50 than > 50 year-olds, women an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Powell, Annabel A, Power, Linda, Westrop, Samantha, McOwat, Kelsey, Campbell, Helen, Simmons, Ruth, Ramsay, Mary E, Brown, Kevin, Ladhani, Shamez N, Amirthalingam, Gayatri
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Centre for Disease Prevention and Control (ECDC) 2021
Materias:	Rapid Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8284043/ https://www.ncbi.nlm.nih.gov/pubmed/34269172 http://dx.doi.org/10.2807/1560-7917.ES.2021.26.28.2100634

Ejemplares similares

Real-world data on immune responses following heterologous prime-boost COVID-19 vaccination schedule with Pfizer and AstraZeneca vaccines in England
por: Westrop, Samantha J, et al.
Publicado: (2022)

Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine
por: Nguyen, Thuy Trang, et al.
Publicado: (2022)

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
por: Shaw, Robert H, et al.
Publicado: (2021)

Effectiveness of BNT162b2 against COVID-19 in adolescents
por: Powell, Annabel A, et al.
Publicado: (2022)

Summer music and arts festivals as hot spots for measles transmission: experience from England and Wales, June to October 2016
por: le Polain de Waroux, Olivier, et al.
Publicado: (2016)

Serological responses to COVID-19 Comirnaty booster vaccine, London, United Kingdom, September to December 2021
por: Ireland, Georgina, et al.
Publicado: (2022)

Robust antibody responses in 70–80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021
por: Subbarao, Sathyavani, et al.
Publicado: (2021)

Antibodies to SARS-CoV-2 protect against re-infection during outbreaks in care homes, September and October 2020
por: Jeffery-Smith, Anna, et al.
Publicado: (2021)

Long COVID and the mental and physical health of children and young people: national matched cohort study protocol (the CLoCk study)
por: Stephenson, Terence, et al.
Publicado: (2021)

Reactogenicity after heterologous and homologous COVID-19 prime-boost vaccination regimens: descriptive interim results of a comparative observational cohort study
por: Warkentin, Lisette, et al.
Publicado: (2022)

Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines
por: Cohen, Guy, et al.
Publicado: (2022)

Heterologous prime-boost immunization with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort study
por: Kohmer, Niko, et al.
Publicado: (2023)

Heterologous prime boost COVID 19 vaccination
por: Launay, O., et al.
Publicado: (2022)

Biofilm Building: A Simple Board Game to Reinforce Knowledge of Biofilm Formation
por: McOwat, Kelsey, et al.
Publicado: (2018)

Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study
por: Naranbhai, Vivek, et al.
Publicado: (2022)

COVID-19 outbreaks following full reopening of primary and secondary schools in England: Cross-sectional national surveillance, November 2020
por: Aiano, Felicity, et al.
Publicado: (2021)

Detection of the United States Neisseria meningitidis urethritis clade in the United Kingdom, August and December 2019 – emergence of multiple antibiotic resistance calls for vigilance
por: Brooks, Avril, et al.
Publicado: (2020)

COVID-19 vaccine given to children with comorbidities in England, December 2020–June 2021
por: Aiano, Felicity, et al.
Publicado: (2022)

Very low risk of monkeypox among staff and students after exposure to a confirmed case in educational settings, England, May to July 2022
por: Ladhani, Shamez N, et al.
Publicado: (2022)

SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020
por: Fischer, Bastian, et al.
Publicado: (2020)

Systemic reactogenicity following homologues and heterologous prime-boost AZD1222 and BNT162b2 COVID-19 vaccination of 2862 healthcare workers compared with an unvaccinated population
por: Tabatabaeifar, Sorosh, et al.
Publicado: (2023)

Post-COVID-19 condition at 6 months and COVID-19 vaccination in non-hospitalised children and young people
por: Pinto Pereira, Snehal M, et al.
Publicado: (2023)

Long COVID in Children and Young after Infection or Reinfection with the Omicron Variant: A Prospective Observational Study
por: Pinto Pereira, Snehal M., et al.
Publicado: (2023)

Immunogenicity and reactogenicity of heterologous COVID-19 vaccination in pregnant women
por: Chayachinda, Chenchit, et al.
Publicado: (2023)

Heterologous Prime-Boost Combinations Highlight the Crucial Role of Adjuvant in Priming the Immune System
por: Ciabattini, Annalisa, et al.
Publicado: (2018)

Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020
por: Singanayagam, Anika, et al.
Publicado: (2020)

Predictive model for long COVID in children 3 months after a SARS-CoV-2 PCR test
por: Nugawela, Manjula D., et al.
Publicado: (2022)

A Cross-Sectional Study of the Health of Emerging Young Adults in England Following a COVID-19 Infection
por: Newlands, Fiona, et al.
Publicado: (2023)

Long COVID—six months of prospective follow-up of changes in symptom profiles of non-hospitalised children and young people after SARS-CoV-2 testing: A national matched cohort study (The CLoCk) study
por: Stephenson, Terence, et al.
Publicado: (2023)

The CLoCk study: A retrospective exploration of loneliness in children and young people during the COVID-19 pandemic, in England
por: McOwat, Kelsey, et al.
Publicado: (2023)

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study
por: Hillus, David, et al.
Publicado: (2021)

Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study
por: Tawinprai, Kriangkrai, et al.
Publicado: (2023)

Heterologous prime-boost vaccination against COVID-19: is it safe and reliable?
por: Choudhary, Om Prakash, et al.
Publicado: (2021)

COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022
por: Kliker, Limor, et al.
Publicado: (2022)

An outbreak caused by the SARS-CoV-2 Delta (B.1.617.2) variant in a care home after partial vaccination with a single dose of the COVID-19 vaccine Vaxzevria, London, England, April 2021
por: Williams, Sarah V, et al.
Publicado: (2021)

Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021–March, 2022: a national, observational, test-negative, case-control study
por: Powell, Annabel A, et al.
Publicado: (2023)

Antibody response induced by the boost overdose during COVID-19 heterologous prime-boost vaccination strategy
por: Raposo, Francisco, et al.
Publicado: (2021)

Significantly lower infection fatality rates associated with SARS-CoV-2 Omicron (B.1.1.529) infection in children and young people: Active, prospective national surveillance, January-March 2022, England
por: Hani, Erjola, et al.
Publicado: (2023)

Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens
por: Klemis, Verena, et al.
Publicado: (2022)

Potency of an HIV-SAM™ vaccine in a heterologous prime-boost vaccination regimen
por: Banerjee, K, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_69a3fblfv107jmvbcmq3rs8a6m